Curis. Gute news werden kommen - 500 Beiträge pro Seite

[fasa]

Jim McCamant (MTSL) sets a $100 Target for CRIS.


Jim McCamant of the Medical Technology Stock Letter sets a $100 Target for CRIS.

Given the active Investor Conference Calendar schedule starting next week, we are expecting increased investment community awareness & interest in CRIS.

Curis, Inc. Investor relations calendar:

Events:
Wall St. Forum, 38th Institutional Investor Conference
Informed Investors (Virtual BioPharma Forum)
UBS Warburg (Healthcare Conference)
ING/Barings (Genomics and Drug Discover Conference)
BioSilico 2000 (BioEdge.net)
Techvest (Tissue Repair Replacement and Regeneration)
Prudential Vector (Healthcare Conference)
Robertson Stephens (Medical Conference)


To view Curis, Inc.`s calendar of events, click on the following link:

http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=CRIS&…

[Mawell]

@ fasa

Mich würde interessieren, wann diese Mitteilung veröffentlicht wurde.
Für eine Antwort wäe ich Dir dankbar!

Mfg,
Mawell

[fasa]

Zu lesen unter www.ragingbull.com

Kürzel cris angeben.

[Steve de Ville]

Hi Leute
hier die 7 Termine

UBS Warburg Healthcare Conference
10/2/00
Location
New York, NY

ING/Barings Genomics and Drug Discover Conference
10/2/00 through 10/3/00
Location
New York, NY

BioContact Quebec 2000
Quebec City
Chateau Frontenac
10/5/00 through 10/6/00

BioSilico 2000 BioEdge.net
10/26/00
Location
New York, NY


Prudential Vector Annual Healthcare Conference
Hotel Inter-Continental
New York
11/8/00 through 11/9/00


Techvest Tissue Repair Replacement and Regeneration
11/8/00 through 11/9/00
Location
New York, NY


Robertson Stephens Medical Conference
11/27/00 through 11/30/00
Location
New York, NY

Wall St. Forum 38th Institutional Investor Conference
2/13/01 through 2/15/01
Location
New York, NY

gruß Steve de Ville auf steigende Kurse

[Mawell]

@ fasa

Danke!

Mfg,
Mawell

[wings111]

Hallo miteinander!

Ich habe gerade folgende News:

Curis Announces Completion of Enrollment In Pivotal Phase III Clinical Trial With Chondrogel; Minimally Invasive Cell-Based Product Targets Severe Pediatric Urological Disorder
BusinessWire, 09/19/2000 09:04

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 19, 2000--Curis, Inc. (NASDAQ:CRIS) today announced the completion of enrollment in a pivotal Phase III clinical trial with Chondrogel, a cell-based, minimally invasive tissue augmentation product for the treatment of a pediatric urological disorder known as vesicoureteral reflux. Data from this trial is expected to be available in late 2001.

Vesicoureteral reflux (VUR) is a congenital condition in children in which urine flows backward from the bladder through the ureter toward the kidney and results in urinary tract infection and kidney damage. Chondrogel is a structural tissue product comprised of autologous cartilage cells taken from the patient`s own ear, expanded in culture and injected into the bladder.

"Chondrogel exemplifies how regenerative medicine and tissue engineering can be used to restore function, improve the quality of health for the patient, decrease morbidity and decrease costs," said Doros Platika, M.D., president and chief executive officer of Curis.

Typically, surgeries for VUR are two-to-three hour procedures, involve two to five day hospital stays and require a four to six week recuperation. Due to the inherent risks and invasiveness of open reflux surgery, both physicians and parents seek to avoid this procedure. The endoscopic implantation of Chondrogel at the defective vesicoureteral junction, if effective, should obviate the need for surgery in significant cases of reflux and may provide an attractive option for standard care, which can include chronic administration of antibiotics, frequent urine cultures and invasive examinations to monitor the condition.

Up to three percent of all children experience VUR, with 24,500 suffering a form of the condition that does not resolve itself. The total market for these non-resolving VUR patients, if treated with Chondrogel, is estimated to be in excess of $300 million. Approximately 15,000 surgical procedures per year are performed to address this problem, representing a market of $200 million based on replacement treatment with Chondrogel.

The Phase III trial includes 61 patients between the ages of six months and 18 years, treated at eight sites in the U.S. The primary endpoint, or outcome measure, of this trial is the resolution of reflux as determined by an x-ray image of the bladder and ureters known as a voiding cystourethrogram.

Pending evaluation of data from this trial, Curis expects to submit a BLA (Biologics License Application) to the U.S. Food and Drug Administration in the first half of 2002. Curis intends to market Chondrogel directly to the approximately 250 pediatric urologists who treat VUR in the U.S.

Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.

The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry and mergers generally. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis joint proxy statement/prospectus filed with the Securities and Exchange Commission on June 19, 2000.

CONTACT: for Curis, Inc.:

William B. Boni

[phone], ext. 6506
or
for Noonan / Russo Communications:

Anthony Russo

[phone], ext. 202

Renee Connolly

[phone], ext. 227

KEYWORD: MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL MEDICAL DEVICES Today`s News On The Net - Business Wire`s full file on the Internet


zu finden unter: http://investing.lycos.com/lycos/story.asp?startStory=166986…

[Wuscher]

moin moin
kann mier das mal jemand
in kurzform ins deutsche übersetzen
danke im foraus